Pfizer Ltd. (PFIZER): Pfizer 52 Week Low Streak: Four-Day Breakdown Deepens
- September 10, 2026
- Posted by: Harsh Piplani
- Category: News
Pfizer Ltd. (PFIZER) has now set a fresh 52-week low for its fourth consecutive session, extending a repeated-breakdown pattern that has taken the stock down 11.63% across the streak. The latest trough stands at Rs 4,045.70, while the current price is Rs 4,060. The supplied data confirms the price pattern, but it does not establish any company-specific cause for the continued move.
Against the previous close of Rs 4,062.05, the stock slipped Rs 2.05, or 0.05%, after opening at Rs 4,070.90 and touching an intraday high of Rs 4,074.95. Turnover stood at Rs 0.27 crore and market capitalisation at Rs 18,582.96 crore. For readers tracking the Pfizer 52 Week Low Streak, the key issue is not a single-day decline but the fact that the one-year low has been reset on each of the last four sessions.
Pfizer Ltd. 52 Week Low Streak: Consecutive Low Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 4,060 |
| Previous Close | Rs 4,062.05 |
| Today's Move | Rs -2.05 (-0.05%) |
| Open | Rs 4,070.9 |
| High | Rs 4,074.95 |
| Low | Rs 4,045.7 |
| Turnover | Rs 0.27 crore |
| Market Capitalisation | Rs 18,582.96 crore |
Pfizer Ltd. (PFIZER) traded at Rs 4,060 versus the previous close of Rs 4,062.05, a fall of 0.05%. The stock opened at Rs 4,070.9, reached a high of Rs 4,074.95, touched a low of Rs 4,045.7.
Pfizer share price today closed just below the previous close, and the move remained narrow in rupee terms, but the broader context is more important: the stock has kept marking lower one-year lows across consecutive sessions. The latest close of Rs 4,060 is only marginally below the previous close of Rs 4,062.05, yet it sits at the lower end of the ongoing Pfizer 52 Week Low Streak and confirms that the repeated breakdown has not yet been arrested. The day’s open at Rs 4,070.90 and high of Rs 4,074.95 show that the stock did not move far away from the lower band of the session.
The intraday low of Rs 4,045.70 matched the fresh 52-week low, which makes the close especially relevant for short-term tracking. In practical terms, the stock finished only Rs 14.30 above the day’s low, suggesting that the session ended close to the weakest point of the day. Turnover of Rs 0.27 crore indicates a small traded value for the session, while the market capitalisation of Rs 18,582.96 crore places Pfizer in a sizeable listed-company bracket. For a reader scanning the Pfizer Share Price Today move, the more useful signal is the back-to-back yearly low pattern rather than the day’s modest percentage change.
What the Repeated 52-Week Lows Show
The Pfizer 52 Week Low Streak is now the central story because it shows persistence rather than a one-off break below a support zone. Across four consecutive sessions, the stock has printed a new yearly low each day, and the cumulative decline of 11.63% is the clearest measure of how far the pattern has extended. That cumulative move matters more than the latest daily change because it captures the full streak, not only the most recent close. The same sequence also indicates that the stock has not yet found a lower band that attracts stable pricing.
The current 52-week low of Rs 4,045.70 is the latest point in that sequence, and the repeated resets mean the prior low from the earlier session has already been overtaken. On that basis, the market has moved from a single-day break to a multi-session weakness pattern. The supplied data confirms the continued price deterioration, but it does not confirm a fresh company-specific event, operational development or sector-wide trigger behind it. For the Pfizer 52 Week Low Streak, that distinction is important: the chart pattern is real, while the cause remains unconfirmed in the available data.
Read another way, the stock is not merely drifting lower inside a range; it is creating a new one-year trough on each session of the streak. That is why investors following Pfizer New One Year Low headlines often focus on whether the sequence is lengthening, whether the next session prints yet another fresh low, and whether the price begins to stabilise above the latest trough.
Pfizer Ltd. (PFIZER) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 18,582.96 crore |
| P/E Ratio | 25.28x |
| P/B Ratio | 4.22x |
| ROE | 17.16% |
| ROCE | 23.39% |
| EPS | Rs 160.7 |
| Book Value Per Share | Rs 963.41 |
| Dividend Yield | 1.85% |
Pfizer Ltd. (PFIZER) fundamental metrics show P/E 25.28x, P/B 4.22x, ROE 17.16%, ROCE 23.39%. These figures provide context only and are not a buy or sell signal.
Pfizer Ltd. has a market capitalisation of Rs 18582.96 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 25.28x, P/B at 4.22x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 17.16% and ROCE of 23.39%, helping investors compare shareholder returns and capital efficiency. Additional supplied metrics include EPS of Rs 160.7, book value per share of Rs 963.41, dividend yield of 1.85%, adding context to earnings, balance-sheet value and historical payout. Against the supplied same industry benchmark, these figures can be compared with benchmark median P/E of 33.2x, median ROE of 11.61%, median ROCE of 13.18%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 25.28x |
| Benchmark Median P/E | 33.2x |
| Benchmark Average P/E | 49.29x |
| Benchmark P/E Range | 3.34x to 693.7x |
| Company P/B Ratio | 4.22x |
| Benchmark Median P/B | 3.04x |
| Company ROE | 17.16% |
| Benchmark Median ROE | 11.61% |
| Company ROCE | 23.39% |
| Benchmark Median ROCE | 13.18% |
| Company Market Capitalisation | Rs 18,582.96 crore |
| Benchmark Median Market Cap | Rs 692.38 crore |
Pfizer Ltd. (PFIZER) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Pfizer Ltd. (PFIZER) has a P/E ratio of 25.28x, which is below the benchmark median of 33.2x, a difference of -23.86%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Pfizer Ltd. (PFIZER) has a ROE of 17.16%, which is above the benchmark median of 11.61%, a difference of +47.8%. Pfizer Ltd. (PFIZER) has a ROCE of 23.39%, which is above the benchmark median of 13.18%, a difference of +77.47%.
Track stocks falling to yearly lows through the Univest 52-week-low screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Eris Lifesciences Ltd. | ERIS | 18,805.75 | 29.21 | 4.66 | 19.23 | 14.47 |
| Shilpa Medicare Ltd. | SHILPAMED | 18,812.04 | 63.27 | 7 | 9.82 | 11.43 |
| Glenmark Life Sciences Ltd. | ALIVUS | 17,005.69 | 28.2 | 4.88 | 18.41 | 24.61 |
| Astrazeneca Pharma India Ltd. | ASTRAZEN | 16,963.38 | 100.01 | 18.76 | 23.02 | 31.24 |
| Suven Pharmaceuticals Ltd. | COHANCE | 16,834.28 | 158.47 | 4.37 | 4.02 | 6.12 |
Pfizer Ltd. (PFIZER) has a P/E ratio of 25.28x compared with the displayed peer median of 63.27x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 17.16% compares with a peer median of 18.41% across the companies shown in the table. ROCE stood at 23.39% versus the displayed peer median of 14.47%, providing a capital-efficiency comparison. Pfizer Ltd. (PFIZER) has a market capitalisation of Rs 18,582.96 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching
- The stock has now posted a fresh 52-week low for its fourth consecutive session, making the Pfizer 52 Week Low Streak the main market event to watch.
- The cumulative decline across the streak is 11.63%, which is more informative than the latest daily move alone.
- The latest trough at Rs 4,045.70 is below the prior session’s low, confirming that the one-year low keeps moving lower.
- The supplied data confirms the price pattern, but it does not establish a company-specific cause for the repeated weakness.
- Investors watching 52 Week Low Stocks may want to monitor whether the next session prints another fresh low or whether the price begins to settle above the latest trough.
About the Company
Pfizer Ltd. is a listed pharmaceutical company on NSE and BSE, operating in the Pharmaceuticals & Drugs industry under the broader Healthcare sector. The company’s market capitalisation is Rs 18,582.96 crore, and the supplied financial metrics show earnings per share of Rs 160.7, book value of Rs 963.41 and dividend yield of 1.85%. Those numbers help place the Pfizer Share Price in a fundamental context while the market continues to mark new one-year lows.
For readers following Pfizer Company News or broader Healthcare stock trends, the business profile matters because the current discussion is not only about a low price point but about the persistence of the Pfizer 52 Week Low Streak. The stock’s current market position should be read alongside its valuation ratios, profitability measures and size within the listed healthcare universe.
Track Pfizer Ltd. on Univest
Follow the Pfizer 52 Week Low Streak, the latest Pfizer Share Price Update and related Pfizer Stock Analysis on Univest for structured market coverage. Readers can also track sector context, peer comparison and other Stocks Hitting 52 Week Lows through the same stock page.
Frequently Asked Questions
Why is Pfizer still hitting 52-week lows?
Ans. The supplied data confirms that Pfizer has made fresh one-year lows on four consecutive sessions, but it does not establish a company-specific cause. The article can therefore explain the pattern, not the trigger.
How many sessions has Pfizer been making fresh 52-week lows?
Ans. Pfizer has now set a fresh 52-week low for its fourth consecutive session. That is the defining feature of the current Pfizer 52 Week Low Streak. The stock moved -0.05% during the session.
What is the latest 52-week low for Pfizer?
Ans. The latest 52-week low supplied is Rs 4,045.70. The current price of Rs 4,060 is only slightly above that trough, showing how close the close remained to the day’s weakest point.
How does Pfizer compare with peers on valuation?
Ans. Pfizer’s P/E of 25.28 is below the industry median of 33.2, while its P/B of 4.22 is above the median of 3.04. That makes the valuation mixed rather than uniformly cheap or expensive.
Is Pfizer inexpensive compared with the sector?
Ans. On earnings, Pfizer trades below the sector median P/E. On book value, it trades above the sector median P/B. So the valuation picture is balanced, and the price decline is not explained by one simple ratio.
What do Pfizer’s return ratios show?
Ans. Pfizer’s ROE is 17.16% and ROCE is 23.39%, both above the supplied sector medians. That indicates solid return metrics in the comparison set, even though the share price remains under pressure.
What should investors monitor next?
Ans. Investors should watch whether the next session produces another fresh 52-week low or whether the price stabilises above Rs 4,045.70. The repeat-low pattern is the main signal in the current Pfizer 52 Week Low Streak.
Track Pfizer Ltd. (PFIZER) Share Price on Univest
Use Pfizer Ltd. (PFIZER) live share-price page, Univest 52-week-low screener, Univest market blogs to review live stock data, yearly-low lists and related market analysis.